ASCO-GU – Arcus goes it alone in HIF2α
Casdatifan yields its first median PFS number, but Gilead doesn’t opt in.
ASCO-GU – Corbus backs Chinese data with its own
But investors remain unimpressed with the Nectin-4 ADC Corbus bought for just $7.5m.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
Xilio's second bailout
AbbVie follows Gilead in throwing Xilio a lifeline.
ASCO-GU – Pfizer eyes broader Talzenna use
But the overall survival benefit in prostate cancer is still driven by HRR mutations.
